Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed participation in trial F13CD-3760 (NCT01230021)~Exclusion Criteria:~* Known or suspected hypersensitivity to trial product or related products~* Known history of development of inhibitors against FXIII (factor XIII)~* Hereditary or acquired coagulation disorder other than FXIII congenital deficiency~* Platelet count (thrombocytes) less than 50X10e9 / L~* Previous history of autoimmune disorder involving autoantibodies e.g., systemic lupus erythematosus~* Previous history of arterial or venous thromboembolic events e.g., cerebrovascular accident or deep vein thrombosis~* Any disease or condition which, judged by the trial physician, could imply a potential hazard to the subject, interfere with the trial participation or trial outcome including renal and/or liver dysfunction

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- rFXIII 35 IU/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).